ATE245420T1 - Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung - Google Patents
Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierungInfo
- Publication number
- ATE245420T1 ATE245420T1 AT96903540T AT96903540T ATE245420T1 AT E245420 T1 ATE245420 T1 AT E245420T1 AT 96903540 T AT96903540 T AT 96903540T AT 96903540 T AT96903540 T AT 96903540T AT E245420 T1 ATE245420 T1 AT E245420T1
- Authority
- AT
- Austria
- Prior art keywords
- advanced glycosylation
- formation
- protein
- glycosylation endproducts
- reverse
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/375,155 US5656261A (en) | 1995-01-18 | 1995-01-18 | Preventing and reversing advanced glycosylation endproducts |
PCT/US1996/000663 WO1996022095A2 (en) | 1995-01-18 | 1996-01-18 | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts |
US08/588,249 US5853703A (en) | 1995-01-18 | 1996-01-18 | Preventing and reversing the formation of advanced glycosylation endproducts |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE245420T1 true ATE245420T1 (de) | 2003-08-15 |
Family
ID=27006923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT96903540T ATE245420T1 (de) | 1995-01-18 | 1996-01-18 | Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung |
Country Status (14)
Country | Link |
---|---|
US (1) | US5853703A (de) |
EP (2) | EP1327887A3 (de) |
JP (1) | JP4067562B2 (de) |
CN (1) | CN1142778C (de) |
AT (1) | ATE245420T1 (de) |
BR (1) | BR9607598B1 (de) |
CA (1) | CA2210684C (de) |
DE (1) | DE69629176T2 (de) |
DK (1) | DK0808163T3 (de) |
ES (1) | ES2203677T3 (de) |
MX (1) | MX9705449A (de) |
NZ (1) | NZ302027A (de) |
PT (1) | PT808163E (de) |
WO (1) | WO1996022095A2 (de) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656261A (en) | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
FI119756B (fi) * | 1995-01-18 | 2009-03-13 | Alteon Inc | Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa |
WO1997023783A1 (en) * | 1995-12-26 | 1997-07-03 | The Picower Institute For Medical Research | Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts |
US20040198795A1 (en) * | 1996-05-08 | 2004-10-07 | Wagle Dilip R | Substituted imidazoliums and methods of use therefor |
US6119701A (en) * | 1998-02-13 | 2000-09-19 | Cerami Consulting Corp. | Methods, agents and devices for removing nucleophilic toxins from tobacco and tobacco smoke |
US6121300A (en) * | 1998-11-10 | 2000-09-19 | Wagle; Dilip R. | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
US20020103228A1 (en) * | 1999-10-06 | 2002-08-01 | Torrent Pharmaceuticals Ltd. | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications |
RU2215000C2 (ru) | 1999-10-06 | 2003-10-27 | Торрент Фармасьютикалз Лтд. | Производные солей пиридиния, способ их получения, фармацевтические композиции на их основе и способы лечения |
US6608094B2 (en) | 1999-10-06 | 2003-08-19 | Torrent Pharmaceuticals Ltd. | Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
PL348049A1 (en) * | 1999-10-06 | 2002-05-06 | Torrent Pharmaceuticals Ltd | Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications |
NZ520143A (en) * | 2000-01-19 | 2005-01-28 | Alteon Inc | Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging |
CN1406127A (zh) * | 2000-02-23 | 2003-03-26 | 奥尔顿有限公司 | 噻唑鎓类化合物和与蛋白老化有关的疾病的治疗 |
AU2001249683A1 (en) * | 2000-03-29 | 2001-10-08 | Alteon Inc. | Synthesis of thiazolium compounds |
US7439330B2 (en) * | 2000-05-08 | 2008-10-21 | President And Fellows Of Harvard College | Anti-glycated CD59 antibodies and uses thereof |
US6835545B2 (en) * | 2000-05-08 | 2004-12-28 | President And Fellows Of Harvard College | Methods, products and treatments for diabetes |
AU2001280551B9 (en) * | 2000-07-13 | 2006-01-12 | Alteon, Inc. | Method for treating fibrotic diseases or other indications ic |
EP1353676A4 (de) * | 2000-12-29 | 2006-05-31 | Alteon Inc | Methode zur behandlung von fibrosen oder anderen indikationen |
MXPA03005954A (es) * | 2000-12-29 | 2004-05-24 | Alteon Inc | Metodo para tratar enfermedades fibroticas u otras indicaciones iiic. |
MXPA03005922A (es) * | 2000-12-29 | 2004-05-04 | Alteon Inc | Metodo para tratar glaucoma ib. |
AU2002243636A1 (en) * | 2001-01-22 | 2002-07-30 | Farrington Pharmaceuticals, Llc | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment |
CZ303214B6 (cs) * | 2001-03-21 | 2012-05-30 | Torrent Pharmaceuticals Ltd | Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití |
DK1243581T3 (da) * | 2001-03-21 | 2005-10-31 | Torrent Pharmaceuticals Ltd | Pyridiniumforbindelser til behandling af AGE-relaterede sygdomme |
AU766824B2 (en) * | 2001-03-28 | 2003-10-23 | Torrent Pharmaceuticals Ltd | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses |
PT1373263E (pt) * | 2001-04-05 | 2005-03-31 | Torrent Pharmaceuticals Ltd | Compostos heterociclicos para complicacoes relacionadas com a idade e complicacoes vasculares diabeticas |
JP2004536807A (ja) * | 2001-05-30 | 2004-12-09 | アルテオン インコーポレイテッド | 緑内障vの治療方法 |
WO2002096362A2 (en) * | 2001-05-30 | 2002-12-05 | Alteon Inc. | Method for treating fibrotic diseases or other indications vi |
CA2448306A1 (en) * | 2001-05-30 | 2002-12-05 | Alteon Inc. | Method for treating fibrotic diseases or other indications |
US7144570B2 (en) * | 2002-05-23 | 2006-12-05 | Alteon, Inc. | Sunscreen compositions and methods of use thereof |
AU2003239868A1 (en) * | 2002-05-23 | 2003-12-12 | Tony Maniscalco | Sunscreen compositions and methods of use thereof |
DE10225537A1 (de) * | 2002-06-10 | 2003-12-18 | Bayer Ag | N-alkylierte Thiazoliumsalze und Verfahren zu deren Herstellung |
CN1774445A (zh) * | 2002-08-16 | 2006-05-17 | 惠氏公司 | 用于治疗rage相关病症的组合物和方法 |
US6991488B2 (en) | 2002-09-25 | 2006-01-31 | Anthony Freakes | Electrical connector devices and methods for employing same |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
EA008496B1 (ru) * | 2002-12-20 | 2007-06-29 | Чакшу Рисерч, Инк. | Офтальмологический препарат для профилактики и лечения болезненных состояний глаз |
US20060172972A1 (en) * | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
US20060166879A1 (en) * | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
CN1324019C (zh) * | 2003-04-02 | 2007-07-04 | 深圳市东阳光实业发展有限公司 | 氮杂双环盐类化合物及其治疗蛋白老化疾病的用途 |
US20050014747A1 (en) * | 2003-04-18 | 2005-01-20 | Emily Reinhard | Dihydrothiazine prodrugs of thiazolium agents |
US7416756B2 (en) | 2003-09-10 | 2008-08-26 | Eastman Chemical Company | Process for the recovery of a phytolipid composition |
US20050137239A1 (en) * | 2003-12-17 | 2005-06-23 | Hines Michelle D. | Thiazole derivatives |
FI20060768A0 (fi) * | 2006-08-28 | 2006-08-28 | Faron Pharmaceuticals Oy | Erityisesti metabolia-oireyhtymän hoitoon tai ehkäisyyn soveltuvia koostumuksia |
US8119651B2 (en) * | 2004-01-30 | 2012-02-21 | Biotie Therapies Corp. | Compositions useful especially for treatment or prevention of metabolic syndrome |
WO2006017563A2 (en) * | 2004-08-02 | 2006-02-16 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for reversing age-related changes in extracellular matrix proteins |
UA92154C2 (ru) * | 2004-08-03 | 2010-10-11 | Транстек Фарма, Инк. | Rage-слитые белки и способы их применения |
UA93356C2 (ru) * | 2004-08-03 | 2011-02-10 | Tpahctek Фарма, Инк. | Белки слияния ha ochobe rage и способы их использования |
WO2006032165A1 (fr) * | 2004-09-23 | 2006-03-30 | Beijing Molecule Science And Technology Co., Ltd | Nouveaux composés n-hétérocycliques substitués à cinq chaînons, et utilisation desdits composés dans le traitement des maladies liées au vieillissement des protéines |
WO2006034605A1 (fr) * | 2004-09-28 | 2006-04-06 | Beijing Molecule Science And Technology Co., Ltd. | Nouveaux ammoniums a noyaux azabicycliques et leur utilisation pour le traitement des troubles lies au vieillissement des proteines |
US7833725B2 (en) | 2005-01-06 | 2010-11-16 | President And Fellows Of Harvard College | Mass spectrometric methods and products |
US20070098709A1 (en) * | 2005-06-29 | 2007-05-03 | Gaetano Barile | Methods for treating and preventing diabetic retinopathy |
CA2615231A1 (en) * | 2005-07-15 | 2007-01-25 | Chakshu Research Inc. | Prevention and treatment of ophthalmic complications of diabetes |
US7569210B2 (en) * | 2005-09-26 | 2009-08-04 | Jamie Collins Doss | Therapeutic soap product with UV protection |
CA2634908C (en) * | 2005-12-23 | 2015-05-19 | Gcoder Systems Ab | Positioning pattern |
CN101007789B (zh) * | 2006-01-27 | 2014-08-20 | 北京摩力克科技有限公司 | 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途 |
CN104151261B (zh) * | 2006-01-27 | 2017-02-15 | 北京摩力克科技有限公司 | 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途 |
US20090004190A1 (en) * | 2006-02-09 | 2009-01-01 | Mjalli Adnan M M | Rage Fusion Proteins And Methods Of Use |
EP2021474A2 (de) * | 2006-05-05 | 2009-02-11 | Transtech Pharma, Inc. | Rage-fusionsproteine, formulierungen daraus und verfahren zu ihrer verwendung |
US20080199467A1 (en) * | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
CN101842382A (zh) | 2007-06-14 | 2010-09-22 | 卡拉狄加制药公司 | Rage融合蛋白 |
WO2009023207A1 (en) * | 2007-08-13 | 2009-02-19 | Synvista Therapeutics, Inc. | Thiazolium compounds for treating gastrointestinal complications |
WO2009042213A1 (en) * | 2007-09-26 | 2009-04-02 | Synvista Therapeutics, Inc. | Methods of treating or preventing cardiac disease associated with a high fat diet |
WO2009051804A1 (en) * | 2007-10-18 | 2009-04-23 | Synvista Therapeutics, Inc. | Thiazolium compounds for treating or preventing diseases associated with insulin resistance |
CN101684106B (zh) * | 2008-09-22 | 2013-06-12 | 北京摩力克科技有限公司 | 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途 |
WO2010122460A1 (en) | 2009-04-20 | 2010-10-28 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
EA201171368A1 (ru) | 2009-05-07 | 2012-04-30 | Торрент Фармасьютикалз Лимитед | Новые гетероциклические соединения |
FR2951085B1 (fr) | 2009-10-09 | 2012-05-18 | Inst Substances Vegetales | Utilisation de composes phenoliques pour la deglycation des proteines |
WO2012027555A2 (en) | 2010-08-25 | 2012-03-01 | President And Fellows Of Harvard College | Glycated cd59 peptides, their preparation, and uses thereof |
US9622469B2 (en) | 2013-10-03 | 2017-04-18 | David Spiegel | Crosslink breakers for preservation of biological substances |
CN106187935A (zh) * | 2016-07-04 | 2016-12-07 | 蚌埠学院 | 一种3‑苯甲基‑5‑(2‑羟乙基)‑4‑甲基噻唑啉氯的合成方法 |
CN112028833B (zh) * | 2020-09-25 | 2022-07-05 | 西南大学 | 对氨基水杨酸唑类衍生物及其制备方法和应用 |
CN112094279B (zh) * | 2020-09-25 | 2022-11-18 | 西南大学 | 对氨基水杨酸双氢青蒿素类衍生物及其制备方法和应用 |
WO2024062164A1 (fr) | 2022-09-23 | 2024-03-28 | A2P Sciences | Acide sagerinique et compositions le contenant pour utilisation dans la prevention et/ou le traitement des troubles lies a la senescence chez un etre humain ou animal |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1364779A (en) * | 1972-05-09 | 1974-08-29 | Soc D Etudes Prod Chimique | Thiazole derivative |
JPS60184038A (ja) * | 1984-03-01 | 1985-09-19 | Nippon Kasei Kk | 1−ヒドロキシ−2−オン類の製造方法 |
US5399560A (en) * | 1984-03-19 | 1995-03-21 | The Rockefeller University | 1,2,4-triazine products resulting from the inhibition of advanced glycosylation |
US5262152A (en) * | 1984-03-19 | 1993-11-16 | The Rockefeller University | Amidrazones and derivatives thereof |
US4758583A (en) * | 1984-03-19 | 1988-07-19 | The Rockefeller University | Method and agents for inhibiting protein aging |
US5869534A (en) * | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
CA1273011A (en) * | 1984-07-02 | 1990-08-21 | Susan M. Schmitt | Carbapenems having an externally alkylated mono- or bicyclic 2-quaternary heteroarylalkylthio substituent |
DE3428483C1 (de) * | 1984-08-02 | 1985-06-20 | Zündwarenfabrik Starcke GmbH & Co, 4520 Melle | Springrollo |
US4683312A (en) * | 1984-11-13 | 1987-07-28 | Eli Lilly And Company | Imidazolium hypoglycemic agents |
US4609670A (en) * | 1984-11-13 | 1986-09-02 | Eli Lilly And Company | Imidazolium hypoglycemic agents |
JP2507764B2 (ja) * | 1987-11-30 | 1996-06-19 | 三井石油化学工業株式会社 | 低級アルキルスルフアモイルアミン類、その塩およびその用途 |
ZA897514B (en) * | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
US5108930A (en) * | 1990-02-20 | 1992-04-28 | Alteon Inc. | Aminoguanidine assay and applications thereof |
US5230998A (en) * | 1991-07-25 | 1993-07-27 | Neurath Alexander R | Method for the prescreening of drugs targeted to the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp 120 |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US5366885A (en) * | 1992-06-09 | 1994-11-22 | Barranco Iii Sam C | Method and kit for testing tumors for drug sensitivity |
DE4222980A1 (de) * | 1992-07-13 | 1994-01-20 | Cassella Ag | Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten |
DK0614886T3 (da) * | 1992-07-30 | 1997-01-13 | Drug Delivery System Inst Ltd | Forbindelser, der kan tilbageholdes i hjernen |
-
1996
- 1996-01-18 MX MX9705449A patent/MX9705449A/es not_active IP Right Cessation
- 1996-01-18 PT PT96903540T patent/PT808163E/pt unknown
- 1996-01-18 ES ES96903540T patent/ES2203677T3/es not_active Expired - Lifetime
- 1996-01-18 NZ NZ302027A patent/NZ302027A/en not_active IP Right Cessation
- 1996-01-18 EP EP03075955A patent/EP1327887A3/de not_active Withdrawn
- 1996-01-18 DK DK96903540T patent/DK0808163T3/da active
- 1996-01-18 EP EP96903540A patent/EP0808163B1/de not_active Expired - Lifetime
- 1996-01-18 DE DE69629176T patent/DE69629176T2/de not_active Expired - Fee Related
- 1996-01-18 WO PCT/US1996/000663 patent/WO1996022095A2/en active IP Right Grant
- 1996-01-18 BR BRPI9607598-8A patent/BR9607598B1/pt not_active IP Right Cessation
- 1996-01-18 CN CNB961923938A patent/CN1142778C/zh not_active Expired - Fee Related
- 1996-01-18 CA CA002210684A patent/CA2210684C/en not_active Expired - Fee Related
- 1996-01-18 AT AT96903540T patent/ATE245420T1/de not_active IP Right Cessation
- 1996-01-18 US US08/588,249 patent/US5853703A/en not_active Expired - Fee Related
- 1996-01-18 JP JP52237996A patent/JP4067562B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2210684A1 (en) | 1996-07-25 |
ES2203677T3 (es) | 2004-04-16 |
PT808163E (pt) | 2003-12-31 |
JPH10512864A (ja) | 1998-12-08 |
NZ302027A (en) | 2001-04-27 |
BR9607598A (pt) | 1999-11-30 |
JP4067562B2 (ja) | 2008-03-26 |
US5853703A (en) | 1998-12-29 |
EP1327887A3 (de) | 2008-12-10 |
MX9705449A (es) | 1998-02-28 |
DK0808163T3 (da) | 2003-11-10 |
CA2210684C (en) | 2008-01-15 |
EP1327887A2 (de) | 2003-07-16 |
WO1996022095A3 (en) | 1997-02-27 |
BR9607598B1 (pt) | 2009-05-05 |
WO1996022095A2 (en) | 1996-07-25 |
DE69629176D1 (de) | 2003-08-28 |
EP0808163B1 (de) | 2003-07-23 |
CN1185736A (zh) | 1998-06-24 |
EP0808163A2 (de) | 1997-11-26 |
DE69629176T2 (de) | 2004-06-03 |
CN1142778C (zh) | 2004-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69629176D1 (de) | Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung | |
ATE388704T1 (de) | Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen | |
Sim et al. | Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with α 2-macroglobulin | |
DE3650080D1 (de) | Verfahren und Mittel zur Hemmung des Proteinveraltens. | |
DE60008509D1 (de) | Neue hemmern von fortgeschrittenen glykosilierung-endprodukten | |
EP0316852A3 (de) | Hemmer von nichtenzymatischer Quervernetzung | |
CA2128248A1 (en) | Amino Acids Useful as Inhibitors of the Advanced Glycosylation of Proteins | |
ATE215068T1 (de) | N-acylaminoalkylhydrazinecarboximidamide | |
ATE224713T1 (de) | Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression | |
Frants et al. | Separator isoelectric focusing for identification of α-1-antitrypsin (Pi M) subtypes | |
DE69029540D1 (de) | Oxidative Denaturierung von Eiweissanalyten | |
Bothe et al. | A sodium dodecyl sulfate-gradient gel electrophoresis system that separates polypeptides in the molecular weight range of 1500 to 100,000 | |
ATE223384T1 (de) | Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung | |
WO1996021450A3 (en) | Bis-[hydrazones] | |
AU2492695A (en) | Analytical element,composition and method using modified apo-horseradish peroxidase | |
Von Zabern et al. | Chain structure of cobra venom factor from Naja naja and Naja haje venom | |
ATE231845T1 (de) | 1,2,4-triazinderivate zur inhibierung der proteinglycosylierung | |
KR927003623A (ko) | 변성단백질의 활성회복 방법 | |
WO1997042175B1 (en) | Substituted imidazolium salts and their use for the inhibition of protein ageing | |
FI950044A (fi) | Menetelmä proteiini C:n hajoamisen estämiseksi | |
Narhi et al. | Stoichiometric complexation of streptomyces subtilisin inhibitor and subtilisin | |
Hamana | Effect of the Degree of Cross-Linkage of Polyacrylamide Gel on the Electrophoretic Mobility of Histones | |
Custer | PARTIAL CHARACTERIZATION OF AN INHIBITOR OF BACTERIAL SPORE OUTGROWTH THAT IS THERMALLY DERIVED FROM NITRITE AND THE FORMATION OF ANALOGOUS INHIBITORS FROM LACTOFERRIN OR TRANSFERRIN FRAGMENTS AND NITRITE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0808163 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |